Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
This origin story is critical
The platform enables several strategic opportunities, including the following: Lifecycle extension and differentiation Improved benefit-risk profile Scalable platform across CNS indications Building on a validated nose-to-brain platform The new in vivo study results build on MetP Pharmas extensive preclinical body of evidence demonstrating rapid and sustained CNS exposure of GLP-1based therapeutics using its proprietary nasal technologies
Semaglutide Pharmacokinetics and Half-Life Expansion One of the most defining characteristics of this specific research peptide in a laboratory setting is its highly optimized pharmacokinetic profile
Spichak, S
US$ 23.53
US$ 28.03
US$ 25.04
US$ 27.42
US$ 25.64
